Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)
The purpose of this study is to determine whether etoricoxib, flavoxate, both are effective in the treatment postoperative pain after TURP.
The research hypothesis:
There is a difference in postoperative morphine consumption in the first 24 hours after transurethral prostatectomy between patients who received etoricoxib or flavoxate or both and placebo.
|Pain||Drug: etoricoxib Drug: flavoxate Drug: etoricoxib, flavoxate Drug: placebo||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy: A Factorial Randomized Controlled Trial|
- The patients' total amount of morphine requirement in the first 24 hour. [ Time Frame: 24 hour ]
|Study Start Date:||September 2005|
|Study Completion Date:||December 2007|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
Placebo Comparator: 1
placebo once and placebo 3 times
Active Comparator: 2
etoricoxib 120 mg
Other Name: arcoxia
Active Comparator: 3
flavoxate 200 mg 3 times
Other Name: urispas
Active Comparator: 4
etoricoxib and flavoxate
Drug: etoricoxib, flavoxate
etoricoxib 120 mg once and flavoxate 200 mg 3 times
Postoperative pain is still a significant problem for surgical patients. Conventional use of narcotics for postoperative pain relief is not without serious side effects such as respiratory depression and sedation.There are other alternatives for postoperative analgesia as NSAIDs especially COX2-inhibitors. For some specific operation such as TURP which Foley's catheter needed to be retained for a few days,urinary anti spasmodics may help the patients to be more comfortable.
Comparison(s): There is a difference in postoperative morphine consumption in the first 24 hours after transurethral prostatectomy between patients who received etoricoxib or flavoxate or both and placebo.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00440739
|Faculty of Medicine Siriraj Hospital, Mahidol University|
|Bangkok, Thailand, 10700|
|Principal Investigator:||Sirilak Suksompong, MD||Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand|